search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Screening for transient leukemia in children with Down syndrome.


- candidate number5296
- NTR NumberNTR1667
- ISRCTNISRCTN wordt niet meer aangevraagd
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR11-feb-2009
- Secondary IDs2007-168 METC ErasmusMC
- Public TitleScreening for transient leukemia in children with Down syndrome.
- Scientific TitleScreening for transient myeloproliferative disorder in children with Down syndrome.
- ACRONYMN/A
- hypothesisPrevention of the progression of TMD to ML-DS by chemotherapeutical profylaxis can be possible.
- Healt Condition(s) or Problem(s) studiedDown syndrome, Transient myeloproliferative disorder
- Inclusion criteria1. All children with Down syndrome;
2. Age < 4 weeks;
3. If blasts are present in pleural or pericardial effusion, or in a liverbiopsy (in absence of blasts in peripheral blood);
4. Signed informed consent.
- Exclusion criteria1. Children in whom the diagnosis Down syndrome can not be confirmed;
2. Complications that make sampling unwanted or impossible.
- mec approval receivedyes
- multicenter trialyes
- randomisedno
- group[default]
- TypeSingle arm
- Studytypeintervention
- planned startdate 1-jan-2008
- planned closingdate1-mrt-2014
- Target number of participants811
- InterventionsTreatment will be advised when there is high MRD (above threshold) at week 8.
- Primary outcome1. To determine the population-based frequency of TMD;
2. To establish and investigate the relation of TMD and ML-DS;
3. To see if treatment of TMD can prevent TMD-associated mortality and the development of ML-DS in later life.
- Secondary outcome1. To detect new genetic factors related to the progression of TMD to ML-DS;
2. To investigate the presence of lymphoid pre-leukemic clones in neonatal blood samples of TMD;
3. To describe the hematological abnormalities and clinical characteristics in patients with and without TMD.
- Timepoints1. Time point 1: < week 4;
2. Time point 2: at week 8;
3. Time point 2A: at week 10, only for those who were treated because of high MRD-levels at week 8;
4. Time point 3: at week 12.
- Trial web sitehttp://www.erasmusmc.nl/alkg-cs/242905/243014/243045/Down?version=1
- statusopen: patient inclusion
- CONTACT FOR PUBLIC QUERIESMD, PhD-student M. Blink
- CONTACT for SCIENTIFIC QUERIES C.M. Zwaan
- Sponsor/Initiator Erasmus Medical Center
- Funding
(Source(s) of Monetary or Material Support)
Stichting Kinderen Kankervrij, Nederland, Stichting Sophia
- PublicationsBlink M, Buitenkamp TD, van Wouwe JP, van Wering ER, van der Velden VHJ, Zwaan CM. Ontwikkelingen in de diagnostiek en behandeling van leukemie bij kinderen met Down syndroom. Tijdschrift voor Kindergeneeskunde. Accepted for publication.
- Brief summaryThis is a prospective national screening study in which preferably all newborns with Down syndrome are screened for TMD. If there is TMD, the children will be evaluated to see if there is a clinical indication for treatment. Treatment is low-dose cytarabin. Also, children who have high Minimal Residual Disease at week 8 will be treated. Goal is to establish MRD-negativity (below threshold) at week 12. All the children go into follow up to see if and when they develop ML-DS.
- Main changes (audit trail)
- RECORD11-feb-2009 - 14-sep-2009


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl